trending Market Intelligence /marketintelligence/en/news-insights/trending/gewxj6yuvwswqpyrrsrpjq2 content esgSubNav
In This List

Surface Oncology's multiple myeloma medicine gets US FDA orphan drug status

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Surface Oncology's multiple myeloma medicine gets US FDA orphan drug status

Surface Oncology Inc. said the U.S. Food and Drug Administration granted orphan drug designation to its medicine SRF231 for treating a type of blood cancer known as multiple myeloma.

The Cambridge, Mass.-based company said investigational drug SRF231 is being evaluated in a phase 1 trial to assess safety and tolerability.

The FDA's orphan drug status is granted to drugs intended to treat rare diseases that affect fewer than 200,000 people in the U.S. The designation provides certain benefits, including a potential seven-year market exclusivity for the drug upon approval.

Surface Oncology went public in April, raising about $108 million in its IPO.